Article Text

Download PDFPDF
Letter to the editor: Helicobacter pylori eradication – the proof is not in the symptoms
  1. Jan Bornschein1,
  2. D Mark Pritchard2,
  3. Peter Malfertheiner3
  1. 1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  2. 2Department of Cellular and Molecular Physiology, University of Liverpool, Liverpool, UK
  3. 3Medical Department 2, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany
  1. Correspondence to Professor Peter Malfertheiner, Medical Department 2, Ludwig-Maximilians-Universitat Munchen, Munchen, Bayern, Germany; peter.malfertheiner{at}med.ovgu.de

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the excellent and comprehensive British Society of Gastroenterology guidelines on the management of functional dyspepsia.1 While this guideline covers a very important topic in gastroenterology and provides valuable recommendations for clinical practice, we would like to take the opportunity to comment on one recommendation that is not in line with other international standards. The authors recommend that ‘successful eradication of Helicobacter pylori after ‘test and treat’ should only be confirmed in patients with an increased risk of gastric cancer’ and refer in the accompanying text to the fourth edition of the European Maastricht consensus guidelines on this topic.2 While this topic was not discussed in detail in version IV of Maastricht, a clear recommendation on this matter was made in its predecessor (version III): ‘H. pylori eradication should be confirmed at least 4 weeks after treatment’.3 This refers to all patients who have …

View Full Text

Footnotes

  • Contributors JB, MP and PM have written and edited this document in equal contribution.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JB: Consultancy funding from Mayoly Spindler laboratories. MP: Consultancy funding from Ipsen, Advanced Accelerator Applications, INFAI and Mayoly Spindler laboratories and research funding to investigate the role of netazepide in gastric NETs from Trio Medicines. PM: Speaker fees, advisory board member and consultancy for Bayer, Biohit, Biocodex, Danone, Mayoly, Malesci, Menarini and Phathom Pharamaceuticals.

  • Provenance and peer review Not commissioned; internally peer reviewed.